Showing results (11-20 of 46) with videos related to
Sort By:
Pageof 5
Journal of Clinical Pharmacology|May 22, 2014
Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studiesChristopher J Endres, David H Salinger, Kathleen Köck, et al.Journal of the American Academy of Dermatology|October 8, 2025
A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativaSeth Forman, Dipak R Patel, Alexa B Kimball, et al.The New England Journal of Medicine|May 17, 2023
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid ArthritisJay Tuttle, Edit Drescher, Jesus Abraham Simón-Campos, et al.Rheumatology (Oxford, England)|November 19, 2016
Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseasesAjay Nirula, Jon Nilsen, Paul Klekotka, et al.The Journal of Allergy and Clinical Immunology|December 30, 2019
Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasisLewis E Tomalin, Chris B Russell, Sandra Garcet, et al.Plos One|November 19, 2014
Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritisJadwiga Bienkowska, Norm Allaire, Alice Thai, et al.Arthritis Care & Research|July 25, 2015
Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic ArthritisHilary D Wilson, Alex Mutebi, Dennis A Revicki, et al.Nature Immunology|March 9, 2004
Distinct regions in the CD28 cytoplasmic domain are required for T helper type 2 differentiationPietro G Andres, Kimberly C Howland, Ajay Nirula, et al.The New England Journal of Medicine|June 12, 2014
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritisPhilip J Mease, Mark C Genovese, Maria W Greenwald, et al.The Journal of Rheumatology|December 16, 2020
Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II StudyMark C Genovese, Alberto Spindler, Akira Sagawa, et al.Pageof 5